JPS6270321A - 動物の生長促進方法 - Google Patents
動物の生長促進方法Info
- Publication number
- JPS6270321A JPS6270321A JP61158087A JP15808786A JPS6270321A JP S6270321 A JPS6270321 A JP S6270321A JP 61158087 A JP61158087 A JP 61158087A JP 15808786 A JP15808786 A JP 15808786A JP S6270321 A JPS6270321 A JP S6270321A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- animal
- growth
- somatostatin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims description 48
- 230000001133 acceleration Effects 0.000 title 1
- 238000000034 method Methods 0.000 claims description 26
- 229960000553 somatostatin Drugs 0.000 claims description 18
- 102000005157 Somatostatin Human genes 0.000 claims description 13
- 108010056088 Somatostatin Proteins 0.000 claims description 13
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 12
- 239000012634 fragment Substances 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 5
- 241000700159 Rattus Species 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 235000019786 weight gain Nutrition 0.000 description 7
- 230000004584 weight gain Effects 0.000 description 7
- 102000014914 Carrier Proteins Human genes 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000000122 growth hormone Substances 0.000 description 4
- 210000004754 hybrid cell Anatomy 0.000 description 4
- 102000018997 Growth Hormone Human genes 0.000 description 3
- 108010051696 Growth Hormone Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 241000283903 Ovis aries Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710142969 Somatoliberin Proteins 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108010000334 delta-globulin Proteins 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/773,814 US4599229A (en) | 1985-09-09 | 1985-09-09 | Method of promoting animal growth using antibodies against somatostatin |
| US773814 | 1985-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6270321A true JPS6270321A (ja) | 1987-03-31 |
Family
ID=25099391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61158087A Pending JPS6270321A (ja) | 1985-09-09 | 1986-07-07 | 動物の生長促進方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US4599229A (en, 2012) |
| EP (1) | EP0216454B1 (en, 2012) |
| JP (1) | JPS6270321A (en, 2012) |
| AT (1) | ATE73350T1 (en, 2012) |
| DE (1) | DE3684211D1 (en, 2012) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764475A (en) * | 1986-12-01 | 1988-08-16 | The University Of British Columbia | Pancreas dependant immunoassay for determining subpopulations of monoclonal antibodies to somatostatin. |
| US4929600A (en) * | 1988-03-18 | 1990-05-29 | University Of Deleware | Endocrine manipulation to improve body composition of poultry |
| US5168102A (en) * | 1988-03-18 | 1992-12-01 | University Of Delaware | Endocrine manipulation to improve body composition of poultry |
| US5728088A (en) * | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
| US5037420A (en) * | 1988-12-13 | 1991-08-06 | Alza Corporation | Delivery system comprising two sections for delivering somatotropin |
| US5110596A (en) * | 1988-12-13 | 1992-05-05 | Alza Corporation | Delivery system comprising means for delivering agent to livestock |
| US5057318A (en) * | 1988-12-13 | 1991-10-15 | Alza Corporation | Delivery system for beneficial agent over a broad range of rates |
| US5059423A (en) * | 1988-12-13 | 1991-10-22 | Alza Corporation | Delivery system comprising biocompatible beneficial agent formulation |
| US5135523A (en) * | 1988-12-13 | 1992-08-04 | Alza Corporation | Delivery system for administering agent to ruminants and swine |
| US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
| US5174999A (en) * | 1988-12-13 | 1992-12-29 | Alza Corporation | Delivery system comprising fluid ingress and drug egress |
| US6165465A (en) * | 1990-05-15 | 2000-12-26 | American Cyanamid Company | Immunologic enhancement of the somatogenic effect of somatotropin with an antibody |
| EP1149590B1 (en) * | 1994-08-05 | 2006-08-30 | Wisconsin Alumni Research Foundation | Use of gut peptide antibodies to improve feed efficiency |
| US5690952A (en) * | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
| US6086878A (en) * | 1997-08-21 | 2000-07-11 | Dcv, Inc. | Method of increasing muscle protein and reducing fat in animals |
| CA2325169A1 (en) | 1999-12-03 | 2001-06-03 | Ndsu Research Foundation | Somatostatins and method |
| WO2017146738A1 (en) * | 2016-02-26 | 2017-08-31 | Nal Pharmaceutical Group Limited | Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same |
| EP3503911A4 (en) * | 2016-08-26 | 2020-07-29 | Nal Pharmaceutical Group Limited | COMPOSITIONS CONTAINING HYBRID ALBUMIN PROTEIN AND ANALOGUES THEREOF, PROCESSES FOR THE PRODUCTION AND USE OF THE SAME |
| US11793179B2 (en) * | 2020-01-07 | 2023-10-24 | Iowa State University Research Foundation, Inc. | Livestock animals with improved growth performance |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60222499A (ja) * | 1984-03-26 | 1985-11-07 | テクランド | 新規ソマトスタチン、その製造法、上記化合物を含有する獣医使用のための製剤、および動物処置法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4363877B1 (en) * | 1977-09-23 | 1998-05-26 | Univ California | Recombinant dna transfer vectors |
| US4366246A (en) * | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| IT1114943B (it) * | 1977-12-27 | 1986-02-03 | Sclavo Inst Sieroterapeut | Processo per la preparazione di somatomammotropina corionica umana |
| US4172124A (en) * | 1978-04-28 | 1979-10-23 | The Wistar Institute | Method of producing tumor antibodies |
| JPS5616415A (en) * | 1979-07-20 | 1981-02-17 | Otsuka Pharmaceut Co Ltd | Preparation of antibody |
-
1985
- 1985-09-09 US US06/773,814 patent/US4599229A/en not_active Expired - Lifetime
-
1986
- 1986-07-07 JP JP61158087A patent/JPS6270321A/ja active Pending
- 1986-07-07 EP EP86305234A patent/EP0216454B1/en not_active Expired - Lifetime
- 1986-07-07 AT AT86305234T patent/ATE73350T1/de not_active IP Right Cessation
- 1986-07-07 DE DE86305234T patent/DE3684211D1/de not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60222499A (ja) * | 1984-03-26 | 1985-11-07 | テクランド | 新規ソマトスタチン、その製造法、上記化合物を含有する獣医使用のための製剤、および動物処置法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0216454A3 (en) | 1989-01-11 |
| US4599229A (en) | 1986-07-08 |
| DE3684211D1 (en, 2012) | 1992-04-16 |
| ATE73350T1 (de) | 1992-03-15 |
| EP0216454B1 (en) | 1992-03-11 |
| EP0216454A2 (en) | 1987-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6270321A (ja) | 動物の生長促進方法 | |
| MacDermott et al. | Alterations of IgM, IgG, and IgA synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease | |
| Lerner et al. | The role of anti-glomerular basement membrane antibody in the pathogenesis of human glomerulonephritis | |
| EP0097518B1 (en) | Monoclonal antibody | |
| Moloney et al. | Antigenicity of insulin: diabetes induced by specific antibodies | |
| Esterling et al. | Stress-induced alteration of T-lymphocyte subsets and humoral immunity in mice. | |
| US5192537A (en) | Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine | |
| Sasaki et al. | Kinetic analysis of the binding of immunoglobulins IgG1 and IgG2 to bovine mammary cells | |
| Davis et al. | Preparation and in vitro assay of effective and ineffective antilymphocyte sera | |
| Gajl-Peczalska et al. | Localization of immunological complexes fixing ẞ1c (C3) in germinal centers of lymph nodes | |
| JPH02500004A (ja) | 非還元・非酵素的糖鎖形成蛋白に対するモノクローナル抗体 | |
| Nossal et al. | IN VITRO STIMULATION OF ANTIBODY FORMATION BY PERITONEAL CELLS: I. Plaque Technique of High Sensitivity Enabling Access to the Cells | |
| Fried et al. | Studies on the erythropoietic stimulating factor in the plasma of mice after receiving testosterone | |
| Klinman et al. | The role of antibody bivalence in the neutralization of bacteriophage | |
| DE68921374T2 (de) | Monoklonaler Antikörper gegen menschliche Mangan-Superoxiddismutase, Verfahren zu dessen Herstellung, Testreagens, Kit und Testmethode unter Verwendung desselben, Verfahren zur Diagnose von menschlichem Eierstockkrebs und von Herzinfarkt. | |
| Peter et al. | Cell-mediated cytotoxicity during rejection and enhancement of allogeneic skin grafts in rats | |
| JPS63126898A (ja) | コロニー刺激因子に対するモノクローナル抗体 | |
| Gelfand et al. | Mechanism of Allograft Rejection in New Zealand Mice: II. Role of a Serum Factor | |
| JPH01501793A (ja) | 透明帯に対する免疫化による避妊のための方法 | |
| Russell et al. | Macrophage biology and activation | |
| Thompson et al. | Identification of mouse mammary adipose cells by membrane antigens | |
| Tufveson et al. | Studies of the spontaneous rosette-forming cells in the bursa of Fabricius of the chicken | |
| JPS63258493A (ja) | 抗ガングリオシドｇｍ↓１単クロ−ン性抗体、これを産生する細胞及びこれから成る試薬 | |
| Newsom et al. | The effect of cortisone acetate on the production of circulating hemolytic antibodies in the mouse | |
| Clapper et al. | Identification of a teratogenic drug‐protein complex in sera of phenytoin‐treated monkeys |